Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
The Company’s portfolio of Phase 3 product candidates are:
- Remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD) in children
- Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection
- REVASCOR® for advanced chronic heart failure
- MPC-06-ID for chronic low back pain due to degenerative disc disease
The Company also has a promising emerging pipeline and next generation technologies.
Innovative technology platform
Mesoblast’s novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses.
Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes. Another key feature of Mesoblast’s cells is they can be administered to patients without the need for donor–recipient matching or recipient immune suppression.
Events
June 2022
Operational Highlights and Financial Results for the Period Ended March 31, 2022
February 2022
Operational Highlights and Financial Results for the Period Ended December 31, 2021
January 2022
CEO Presentation at Edison Open House - Global Healthcare 2022
November 24, 2021
Operational Highlights and Financial Results for the Period Ended September 30, 2021
November 29 (AEDT); November 28 (EST)
2021 Mesoblast Limited Annual General Meeting
August 31, 2021
Operational Highlights and Financial Results for the Period Ending June 30, 2021
February 11, 2021
Mesoblast Phase 3 Chronic Low Back Pain Results
Latest News
21 June 2022
Mesoblast CLBP Event with Key Opinion Leaders >
21 June 2022
Chronic Low Back Pain KOL Event Presentation >
14 June 2022
Litigation Update >
01 June 2022
Third Quarter Results Presentation >